The Medicines Patent Pool (MPP) announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen.
The MPP said the licence allows manufacturers to develop and sell generic medicines containing BIC, if approved in the United States, in 116 low-income and middle-income countries where more than 30 million people live with HIV.
Medicines Patent Pool executive director Greg Perry said: “Bictegravir-containing combinations could offer improved, simplified treatment options, crucial for people living in resource-limited settings.
“With this new licence, we look forward to our long-running collaboration with Gilead Sciences continuing to deliver significant results.”
Gilead Sciences executive vice president Gregg Alton said: “The once-daily, single-tablet BIC/FTC/TAF regimen has the potential to simplify the management of HIV, and we are committed to promoting its access globally.
“MPP licensees with the rights to manufacture certain of Gilead’s agents, including TAF and now BIC, will be able to produce the single tablet for low- and middle-income countries shortly after its approval in the United States.”
The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low-income and middle-income countries.